降钙素原
败血症
医学
蛋白质组学
生物标志物
组学
生物信息学
计算生物学
重症监护医学
内科学
生物
生物化学
基因
作者
Oren Turgman,Michiel Schinkel,W. Joost Wiersinga
出处
期刊:Annual update in intensive care and emergency medicine
日期:2023-01-01
卷期号:: 71-81
标识
DOI:10.1007/978-3-031-23005-9_6
摘要
Hundreds of biomarkers for sepsis have been evaluated in clinical and experimental studies and advocated to be used in the emergency room. They can have diagnostic, prognostic, therapeutic or theragnostic value. At the moment, however, only a handful are used by clinicians on a large scale, most notably C-reactive protein (CRP) and procalcitonin (PCT). Emerging protein biomarkers include presepsin, soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), and proadrenomedullin (MR-proADM). Recent advances in omic technologies have shifted the focus from traditional protein biomarkers to the fields of genomics, transcriptomics, proteomics, and metabolomics. These novel biomarkers require further validation in large and diverse cohorts. Furthermore, costs and need for experienced personnel are important factors to consider when evaluating the practical usability of any of these biomarkers. This review discusses recent literature on biomarkers for sepsis that are relevant in the emergency room.
科研通智能强力驱动
Strongly Powered by AbleSci AI